Vinblastine, Bleomycin, and Methotrexate Chemotherapy Plus Extended-Field Radiotherapy in Early, Favorably Presenting, Clinically Staged Hodgkin's Patients: The Gruppo Italiano per lo Studio dei Linfomi Experience

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 527-533

  Gobbi, Paolo G ^a   Pieresca, Carlo ^b   Frassoldati, Antonio ^b   Carotenuto, Mario ^b   Di Renzo, Nicola ^b   La Sala, Antonio ^b   Bertè, Raffaella ^b   Avanzini, Paolo ^b   Federico, Massimo ^b   Silingardi, Vittorio ^b   Ascari, Edoardo ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; METHOTREXATE; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG ADENOCARCINOMA; LUNG TOXICITY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; SALVAGE THERAPY; VINCRISTINE;

EID: 0030045571     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.527     Document Type: Article

References (23)

1. Urba WJ, Longo DL: Hodgkin's disease. N Engl J Med 326:678-687, 1993
2. Henry-Amar M, Aeppli DM, Anderson J, et al: Workshop statistical report. Study of second cancer risk, in Somers R, Henry-Amar M, Meerwaldt JH, et al (eds): Treatment Strategy in Hodgkin's Disease. London-Montrouge, United Kingdom, Libbey, 1990, pp 355-379
3. Rosenberg SA: Exploratory laparotomy and splenectomy for Hodgkin's disease: A commentary. J Clin Oncol 6:574-575, 1988
4. Rosenberg SA: The current status of the Standard randomized clinical trials of the management of Hodgkin's disease, in Cavalli F, Bonadonna G, Rozencweig M (eds): Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Boston, MA, Martinus Nijhoff, 1985, pp 281-292
5. Kaplan HS: Hodgkin's Disease (ed 2). Cambridge, MA, Harvard University, 1980, pp 366-441
6. Swerdlow AJ, Day NE, Vaughan Hudson G, et al: Risk of second primary cancer after Hodgkin's disease by type of treatment: Analysis of 2,846 patients in the British National Lymphoma Investigation. Br Med J 304:1137-1143, 1992
7. Tura S, Fiacchini M, Zinzani PL, et al: Splenectomy and the increasing risk of secondary leukemia in Hodgkin's disease. J Clin Oncol 11:925-930, 1993
8. Horning SJ, Hoppe RT, Hancock SL, et al: Vinblastine, bleomycin and methotrexate: An effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 6:1822-1831, 1988
9. Bates NP, Williams MV, Bessel EM, et al: Efficacy and toxicity of vinblastine, bleomycin and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: A British National Lymphoma Investigation pilot study. J Clin Oncol 12:288-296, 1994
10. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a Committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
11. Carbone PP, Spurr C: Management of patients with malignat lymphoma: A comparative study with cyclophosphamide and vinca alkaloid. Cancer 28:98-103, 1968
12. Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14:65-74, 1987
13. DeVita VT Jr, Hubbard SM, Longo DL: The chemotherapy of lymphoma: Looking back, moving forward - The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 47:5810-5824, 1987
14. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:129-137, 1982
15. Armitage P, Berry G: Statistical Methods in Medical Research (ed 2). Oxford, United Kingdom, Blackwell Scientific, 1987, pp 296-357
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Gobbi PG, Comelli M, Grignani GE, et al: Estimate of expected survival at diagnosis in Hodgkin's disease: A means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's Disease (IDHD). Haematologica 79:241-255, 1994
18. Horning SJ, Hoppe RT, Rosenberg SA: VBM chemotherapy: An effective adjuvant to involved field irradiation in favorable Hodgkin's disease (HD). Proc Am Soc Clin Oncol 5:198, 1986 (abstr 779)
19. Kaplan RS, Wiernick PH: Neurotoxicity of antineoplastic drugs. Semin Oncol 9:103-130, 1982
20. Vespignani M, Gasparini G, Chisesi T, et al: Trattamento integrato chemio-radioterapico nel linfogranuloma di Hodgkin (LMH I-II stadio non bulky e senza segni sistemici. Dati preliminari. Tumori 79:74, 1993 (suppl, abstr 231)
21. Eckhardt S: New agents in the therapy of malignant lymphomas, in Bucalossi P, Veronesi U, Bonadonna G, et al: (eds): I Linfomi Maligni. Milano, Italy, Casa Editrice Ambrosiana, 1974, pp 377-379
22. Stewart FA: Modulation of normal tissue toxicity by combined modality therapy: Considerations for improving the therapeutic gain. Int J Radiat Oncol Biol Phys 20:319-325, 1991
23. Comis RL: Bleomycin pulmonary toxicity: Current status and future directions. Semin Oncol 19:64-70, 1992